Core Laboratories NV (NYSE:CLB) is scheduled to be announcing its Q316 earnings results on Thursday, October 20th.

Earnings History for Core Laboratories NV (NYSE:CLB)

Shares of Core Laboratories NV (NYSE:CLB) opened at 110.59 on Tuesday. The company’s 50-day moving average is $110.44 and its 200-day moving average is $117.52. Core Laboratories NV has a 1-year low of $84.50 and a 1-year high of $135.49. The stock has a market cap of $4.88 billion, a P/E ratio of 58.67 and a beta of 1.45.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, November 22nd. Shareholders of record on Friday, October 21st will be paid a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 1.99%. The ex-dividend date is Wednesday, October 19th. Core Laboratories NV’s dividend payout ratio is currently 117.65%.

A number of institutional investors have recently added to or reduced their stakes in CLB. Bessemer Group Inc. increased its position in Core Laboratories NV by 0.3% in the second quarter. Bessemer Group Inc. now owns 1,105,910 shares of the company’s stock valued at $137,011,000 after buying an additional 3,784 shares during the period. BlackRock Institutional Trust Company N.A. increased its position in Core Laboratories NV by 10.2% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 798,509 shares of the company’s stock valued at $98,927,000 after buying an additional 74,219 shares during the period. Massachusetts Financial Services Co. MA increased its position in Core Laboratories NV by 0.4% in the second quarter. Massachusetts Financial Services Co. MA now owns 755,716 shares of the company’s stock valued at $93,625,000 after buying an additional 2,875 shares during the period. State Street Corp increased its position in Core Laboratories NV by 0.4% in the second quarter. State Street Corp now owns 466,446 shares of the company’s stock valued at $57,790,000 after buying an additional 1,726 shares during the period. Finally, Van ECK Associates Corp increased its position in Core Laboratories NV by 0.5% in the second quarter. Van ECK Associates Corp now owns 344,478 shares of the company’s stock valued at $42,677,000 after buying an additional 1,748 shares during the period.

Several equities research analysts have recently commented on the company. JPMorgan Chase & Co. restated a “buy” rating on shares of Core Laboratories NV in a research note on Thursday, June 30th. Zacks Investment Research upgraded Core Laboratories NV from a “hold” rating to a “buy” rating and set a $138.00 price target for the company in a research note on Wednesday, July 20th. Citigroup Inc. cut their price target on Core Laboratories NV from $123.00 to $118.00 and set a “neutral” rating for the company in a research note on Monday, July 25th. Credit Suisse Group AG initiated coverage on Core Laboratories NV in a research note on Thursday, September 1st. They set a “neutral” rating and a $115.00 price target for the company. Finally, Loop Capital initiated coverage on Core Laboratories NV in a report on Friday, September 30th. They set a “hold” rating and a $120.00 price objective on the stock. Three analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $121.61.

About Core Laboratories NV

Core Laboratories N.V. is a provider of reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company’s services and products are directed toward enabling the Company’s clients to improve reservoir performance and increase oil and gas recovery from their producing fields.

5 Day Chart for NYSE:CLB

Receive News & Stock Ratings for Core Laboratories NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories NV and related stocks with our FREE daily email newsletter.